NEWS DETAIL

The Subscription Period Begins in Genetic Analysis as Issue of Units Prior to Planned Listing on Spotlight Stock Market

OSLO, NORWAY – 30 August 2021: Today, the subscription period begins in Genetic Analysis (“GA” or “the Company”) issue of units (“the IPO”) prior to the planned listing on Spotlight Stock Market (“Spotlight”). The subscription period runs until 13 September 2021. If the IPO is fully subscribed, the Company will initially receive approximately NOK 60.1 million and further a maximum of approximately NOK 43 million and NOK 57.7 million, before issue costs, through warrant exercise of TO 1 and TO 2. GA has in advance agreed to approximately 80.4 percent of the initial part of the IPO through written subscription commitments from existing shareholders and external cornerstone investors. The issue proceeds are intended to fund the continued expansion and scaling of the Company's business and product portfolio. The prospectus is available via the Company's (www.genetic-analysis.com), Sedermera Fondkommission's (www.sedermera.se) and Spotlight Stock Market's (www.spotlightstockmarket.com) respective web pages. Nordnet Bank AB is acting Selling Agent in the IPO.

CEO Ronny Hermansen comments
“Genetic Analysis GA-map® enables cost-efficient and reliable mapping and profiling of gut microbiota via In Vitro Diagnostics (IVD) testing. In recent years research has placed the human microbiome as an essential part of our well-being. At the same time, many diseases and conditions have been linked to an imbalance in the gut microbiota composition. Genetic Analysis is currently the only company globally that offers a CE-marked standardized testing platform for microbiome analysis, the GA-map® Dysbiosis Test. GA has initiated an ambitious growth plan to rapidly grow the business over the next few years in the EU and US. We have proven our existing business model to molecular labs, and the Company is now ready, with the CE-marked GA-map®, to be commercialized in the current market for microbiota testing as well as to enter the market for companion diagnostics, where new markers will be developed on the platform in combination with microbiota altering drugs.”